If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...

The victim's counsel argue that CBI's status reports are vague and the agency is actively objecting to petitions that seek deeper inquiries into specific doctors and officers.

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Eli Lilly will pay up to $2.4 billion to ...

Investing in biotechnology stocks has always required a high risk tolerance and the patience to wait years, even decades, for results. These companies drive medical innovation, developing therapies ...

To many biopharmaceutial executives and investors, the start of 2026 felt like a new dawn. A lengthy pullback finally abated towards the end of 2025, as a wave of dealmaking, financings and positive ...